Sera Prognostics, Inc. reports developments in women's health diagnostics, with news centered on its PreTRM® Test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies. The company uses proteomics, bioinformatics and pregnancy biomarker information to support maternal and neonatal health.
Recurring updates include financial results, commercial adoption and payer engagement for PreTRM, clinical evidence from the PRIME study and related publications, investor presentations, healthcare conference activity, capital allocation and financing actions supporting commercialization.
Sera Prognostics (Nasdaq: SERA) reported third-quarter 2026 revenue of $42,000 as PreTRM test adoption increased and Medicaid coverage expanded. Revenue rose 163% year over year, while test volume increased 54% sequentially and ordering providers increased 34%. Lower average selling prices, reflecting more low- or non-reimbursed tests, constrained revenue. Net loss widened to $8.053 million from $7.814 million a year earlier; loss per share remained $0.16.
Florida became the second state providing Medicaid coverage for PreTRM. Illinois established a $525 fee schedule rate without prior authorization. Operating expenses declined 11% sequentially following cost reductions. Quarter-end cash and investment securities totaled $72.8 million, with quarterly operating cash burn of $7.3 million. Sera began the CE Mark submission process for PreTRM Global and published a trial subgroup analysis showing 22% fewer neonatal intensive care admissions among first-time mothers receiving test-guided care.
Sera Prognostics (SERA) will report its third-quarter fiscal year 2026 financial results after market close on November 4, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results and key topics. A results release will be distributed before the call, and the webcast will remain available on the company's Investors page for one year.
Sera Prognostics (Nasdaq: SERA) highlights its PreTRM® Test, a blood-based proteomic test taken between weeks 18–21 of pregnancy to predict individualized risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The test measures the ratio of IBP4 to SHBG to identify women at higher risk so physicians can plan tailored care.
According to Sera, the PRIME randomized controlled trial of ~5,000 participants showed that PreTRM-guided care using vaginal progesterone, low-dose aspirin, and frequent nurse check-ins reduced births before 32 weeks by more than 50%, births before 35 weeks by more than 30%, and NICU admissions by 20%. Sera estimates that full national adoption could reduce U.S. NICU admissions by about 94,300 annually. The company notes growing access through insurance, financial assistance, interest-free payment plans, and Illinois Medicaid coverage for proteomic prenatal testing, including PreTRM, effective July 1, 2026.
Sera Prognostics (Nasdaq: SERA) announced the appointment of Scott Gleason as Chief Financial Officer, effective August 31, 2026. Gleason has more than 25 years of healthcare, diagnostics, and capital markets experience, including roles at Neogen Corporation, LarmorBio, NX Prenatal, OraSure Technologies, and Myriad Genetics.
According to Sera Prognostics, Gleason’s background in financial leadership, investor relations, and strategy is expected to support the company’s next stage of commercial development and expansion of its PreTRM® Test. Current CFO Austin Aerts, who helped guide Sera through its IPO and public company transition, will move to an advisory role focused on strategic initiatives and continuity.
Sera Prognostics (Nasdaq: SERA) reported second quarter 2026 revenue of $30,000, up from $17,000 a year earlier, with total operating expenses of $10.0 million and a net loss of $9.1 million ($0.18 per share). Cash, cash equivalents and available-for-sale securities totaled approximately $80.3 million, which the company believes can fund operations through key commercialization milestones into 2029.
Operationally, Sera launched its fourth partnership program with a national payer, exceeded its 2026 payer engagement objective with discussions across more than 20 payer opportunities in over 20 states, and benefited from an Illinois Medicaid mandate requiring coverage of proteomic tests assessing preterm birth risk, applying to about 50,000 annual Medicaid births. New PRIME trial subgroup and health economic data were presented and published, supporting reduced NICU admissions and severe neonatal morbidity in first-time pregnancies, while European regulatory preparations advanced toward a planned CE mark submission in late 2026.
Sera Prognostics (Nasdaq: SERA) will report its second quarter fiscal year 2026 financial results on Wednesday, August 12, 2026, after the market close, and host a conference call and live webcast at 5:00 p.m. Eastern Time to review operations and results.
US investors can join the call at (800) 836-8184, international participants at (646) 357-8785, and access the webcast via a registration link and the Investors section of www.sera.com. According to the company, the webcast will be archived on the Investors page for one year.
Sera Prognostics (Nasdaq:SERA) reported new PRIME trial subgroup results showing PreTRM® Test-guided care in first-time pregnancies reduced NICU admissions by 22% and severe neonatal morbidity by 30% versus blinded control.
Among 1,783 nulliparous participants, 28 first-time pregnancies needed to be screened and treated to prevent one NICU admission, according to Sera Prognostics. Interventions were well tolerated, and the approach may support healthcare cost savings.
Sera Prognostics (Nasdaq:SERA) appointed Mark Capone to its Board of Directors, effective July 1, 2026. Capone brings over 40 years of leadership in diagnostics and life sciences, including roles as CEO, President and COO at Myriad Genetics and earlier leadership at Eli Lilly.
According to Sera Prognostics, his experience commercializing complex diagnostics, navigating reimbursement and payer environments, and scaling commercial organizations is expected to support expansion of the company’s proteomics-based PreTRM test and its long-term growth strategy in maternal and neonatal health.
Sera Prognostics (Nasdaq:SERA) joined a multi-institutional program awarded up to $10.4 million by ARPA-H’s Making Obstetrics Care Smart (MOCS) initiative. The collaboration with UC San Diego and Allegro MicroSystems aims to develop a rapid point-of-care blood test to assess fetal hypoxia risk during labor.
Sera will apply its protein biomarker discovery and validation expertise to identify signatures of placental dysfunction, fetal stress, or hypoxia risk, supporting more precise, data-driven intervention decisions in childbirth.
Sera Prognostics (Nasdaq:SERA) highlighted new Illinois legislation requiring Medicaid to cover prescribed proteomic blood tests that assess spontaneous preterm birth risk, plus related care management services and interventions. Sera’s PreTRM Test is described as the only broadly validated, commercially available blood-based test of its kind.
Illinois records about 13,042 preterm births annually and approximately 50,000 Medicaid births, where expanded access to early risk assessment tools may support better maternal and neonatal outcomes and help manage financial burdens on Medicaid programs.